<?xml version="1.0" encoding="UTF-8"?>
<p>Monoclonal antibodies (mAbs) characterize a major class of bio-therapeutic products as passive immunotherapies in combating viral infections. 
 <xref ref-type="fig" rid="f0002">Figure 2</xref> shows a stepwise illustration of the COVID-19 serologic diagnostic test through antibody detection. The therapeutic uses of mAbs have been widely accepted and acquired remarkable achievements in the treatment of numerous chronic and lethal viral diseases.
 <sup>
  <xref rid="cit0039" ref-type="bibr">39</xref>
 </sup> From the two nonimmune human antibody libraries, Sui et al.
 <sup>
  <xref rid="cit0040" ref-type="bibr">40</xref>
 </sup> found one recombinant human mAb that efficiently neutralized the SARS-CoV and inhibited the formation of syncytia between the S-protein and SARS-CoV receptor ACE2.
</p>
